BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9728617)

  • 1. Reactive mesothelial hyperplasia vs mesothelioma, including mesothelioma in situ: a brief review.
    Henderson DW; Shilkin KB; Whitaker D
    Am J Clin Pathol; 1998 Sep; 110(3):397-404. PubMed ID: 9728617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.
    Wolanski KD; Whitaker D; Shilkin KB; Henderson DW
    Cancer; 1998 Feb; 82(3):583-90. PubMed ID: 9452278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
    Cury PM; Butcher DN; Corrin B; Nicholson AG
    J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
    Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L
    J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of silver-staining nucleolar organizer region (AgNOR) counts and proliferating cell nuclear antigen (PCNA) expression in reactive mesothelial hyperplasia and malignant mesothelioma.
    Bethwaite PB; Delahunt B; Holloway LJ; Thornton A
    Pathology; 1995 Jan; 27(1):1-4. PubMed ID: 7603742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
    Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
    Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mesothelial hyperplasia with reactive atypia: diagnostic pitfalls and role of immunohistochemical studies-a case report.
    Lee A; Baloch ZW; Yu G; Gupta PK
    Diagn Cytopathol; 2000 Feb; 22(2):113-6. PubMed ID: 10649524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Differential diagnosis of preneoplastic lesions of the pleura and of early mesothelioma: immunohistochemical and morphological findings].
    Krismann M; Thattamparambil P; Simon F; Johnen G
    Pathologe; 2006 Mar; 27(2):99-105. PubMed ID: 16435096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.
    Mayall FG; Goddard H; Gibbs AR
    J Pathol; 1992 Dec; 168(4):377-81. PubMed ID: 1484319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.
    Metze K; Trevisan MA
    Cancer; 1999 Jan; 85(1):250. PubMed ID: 9922003
    [No Abstract]   [Full Text] [Related]  

  • 11. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.
    Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
    J Clin Pathol; 2013 Oct; 66(10):847-53. PubMed ID: 23814259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Detection of p16 by fluorescence in-situ hybridization and immunohistochemistry in malignant mesothelioma].
    Liu Y; Chen X; Ding N; Xu W; Yang H; Chen X
    Zhonghua Bing Li Xue Za Zhi; 2015 Apr; 44(4):262-5. PubMed ID: 25975910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How useful is GLUT-1 in differentiating mesothelial hyperplasia and fibrosing pleuritis from epithelioid and sarcomatoid mesotheliomas? An international collaborative study.
    Husain AN; Mirza MK; Gibbs A; Hiroshima K; Chi Y; Boumendjel R; Stang N; Krausz T; Galateau-Salle F
    Lung Cancer; 2014 Mar; 83(3):324-8. PubMed ID: 24440278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
    Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
    Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of cell cycle state may facilitate the histopathological diagnosis of malignant mesothelioma.
    Sington JD; Morris LS; Nicholson AG; Coleman N
    Histopathology; 2003 May; 42(5):498-502. PubMed ID: 12713628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
    Friedman MT; Gentile P; Tarectecan A; Fuchs A
    Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p16/CDKN2A FISH in Differentiation of Diffuse Malignant Peritoneal Mesothelioma From Mesothelial Hyperplasia and Epithelial Ovarian Cancer.
    Ito T; Hamasaki M; Matsumoto S; Hiroshima K; Tsujimura T; Kawai T; Shimao Y; Marutsuka K; Moriguchi S; Maruyama R; Miyamoto S; Nabeshima K
    Am J Clin Pathol; 2015 Jun; 143(6):830-8. PubMed ID: 25972325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differentiation of malignant from normal and reactive mesothelial cells by the argyrophil technique for nucleolar organiser region associated proteins.
    Ayres JG; Crocker JG; Skilbeck NQ
    Thorax; 1988 May; 43(5):366-70. PubMed ID: 2461601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Florid mesothelial hyperplasia of the tunica vaginalis mimicking malignant mesothelioma: a clinicopathologic study of 12 cases.
    Lee S; Illei PB; Han JS; Epstein JI
    Am J Surg Pathol; 2014 Jan; 38(1):54-9. PubMed ID: 24061516
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical expression of osteopontin in epithelioid mesotheliomas and reactive mesothelial proliferations.
    Tigrani DY; Weydert JA
    Am J Clin Pathol; 2007 Apr; 127(4):580-4. PubMed ID: 17369133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.